Skip to main content

Deafness and Blindness clinical trials at UCSF

1 in progress, 0 open to eligible people

Showing trials for
  • Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

    Sorry, in progress, not accepting new patients

    The purpose of this Phase 2b study is to evaluate the safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene. This is a multicenter Double-masked, Randomized, Sham-controlled study which will enroll 81 subjects.

    San Francisco, California and other locations

Last updated: